Search

everythinglearnresearchcommunity

for

Search:↓

Some treatments can stabilize Frontal Fibrosing Alopecia, but more research is needed to find effective treatments, and hair transplants often fail.

The review suggests there's no agreed treatment for Frontal Fibrosing Alopecia, but hydroxychloroquine and 5a-reductase inhibitors are most effective. New treatments like platelet-rich plasma and LED light could help if standard treatments fail.

Urologic diseases and treatments in older men can negatively affect fertility, and doctors should talk to patients about this.

Finasteride for hair loss may cause lasting sexual, genitourinary, mental, and anti-androgenic side effects in young men.

Tamsulosin with Serenoa repens is as effective as with 5-alpha-reductase inhibitors but causes fewer side effects.

Starting 5-alpha reductase inhibitors does not significantly increase the risk of rhabdomyolysis in older men, but is linked to a higher risk of muscle conditions.

Taking both finasteride and dutasteride for prostate issues may raise the risk of heart problems.

5-Alpha-Reductase inhibitors shorten COVID-19 recovery time in men.

Dutasteride can stabilize hair loss in patients with frontal fibrosing alopecia, but its safety in women is unclear, so use it with caution.

Men taking 5-alpha reductase inhibitors for prostate issues may be less likely to experience severe COVID-19, but it doesn't prevent ICU admission or death.

Taking 5-alpha reductase inhibitors does not increase the risk of breast cancer in men.

Finasteride 1mg linked to diverse symptoms; other treatments improve erectile function in rats.

Medications for hair loss and prostate issues can significantly increase the risk of sexual side effects and other negative symptoms.

The authors suggest that 5-α-reductase inhibitors, like dutasteride, are effective in treating frontal fibrosing alopecia and should be the first-line treatment, with other options for severe cases. They also recommend further research on Janus kinase inhibitors.

Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.

Dutasteride is cheaper than finasteride for treating benign prostatic hyperplasia.

Polygenic risk scores can predict the risk and outcomes of benign prostatic hyperplasia.

5ARI treatment improves hair growth in older men with minimal side effects.

More research needed to confirm finasteride as standard treatment for FFA.

Dutasteride and finasteride can help increase hair growth gene expression but need further improvement.

Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.

Using 5α-reductase inhibitors for hair loss may increase the risk of dry eye disease.

Finasteride and dutasteride can improve hair loss in women, but more research is needed.

Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.

5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.

A higher genetic risk score increases the chance of getting benign prostatic hyperplasia and affects treatment outcomes in Han Chinese men.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.

Alpha-blockers and 5-alpha reductase inhibitors don't significantly increase dementia risk.

Using 5α-reductase inhibitors for hair loss in women doesn't increase cancer risk.